A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
暂无分享,去创建一个
Baljit Singh | C. Isaacs | D. Hayes | R. Slack | V. Stearns | T. Tsangaris | M. Pennanen | M. Ellis | J. Crawford | Cecilia M. Tibery | A. Novielli | Ahmadi Farhad | C. Tibery
[1] M. Untch,et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.
[2] D. Berry,et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Dimopoulos,et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Hayes,et al. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Symmans,et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] A. Goldhirsch,et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Mike Clarke,et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.
[8] D. Wickerham,et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Osborne,et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Hudis,et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Powles,et al. Clinical studies of apoptosis and proliferation in breast cancer. , 1999, Endocrine-related cancer.
[12] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[15] Terry L. Smith,et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. , 1998, Lancet.
[16] C. Osborne,et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Dowsett,et al. Preoperative chemotherapy induces apoptosis in early breast cancer , 1997, The Lancet.
[18] C. Hudis,et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Mamounas,et al. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] U. Chetty,et al. Primary systemic therapy for operable breast cancer. , 1991, British Journal of Cancer.
[21] G. Hortobagyi,et al. Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.
[22] R. Simon,et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.
[23] Philip H. Ramsey. Nonparametric Statistical Methods , 1974, Technometrics.
[24] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[25] T. Powles,et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study , 2004, Breast Cancer Research and Treatment.
[26] M. Gnant,et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] R. Wittes,et al. Evaluation of the Cancer Patient and the Response to Treatment , 1987 .
[28] D. Morton,et al. Treatment of metastatic disease. , 1979, Advances in surgery.
[29] C. Haagensen. Diseases of the Breast , 1971 .